USA flag logo/image

An Official Website of the United States Government

BIOPROCESSING CELLS FROM BLOOD USING BR-FF AND HGMS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16697
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16697
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Immunicon Corporation
Immunicon Corporation 3401 Masons Mill Rd, Ste 100 Huntingdon Valley, PA 19006
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: BIOPROCESSING CELLS FROM BLOOD USING BR-FF AND HGMS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE LONG TERM OBJECTIVE IS TO DEVELOP A NEW TECHNOLOGY FOR INDUSTRY SCALE AFFINITY SEPARATIONS EMPLOYING PROPRIETARY BIO-RECEPTOR FERROFLUIDS (BR-FF) IN COMBINATION WITH EXISTING CONTINUOUS HIGH GRADIENT MAGNETIC SEPARATORS (HGMS) AND IMPROVED SYSTEMS CURRENTLY BEING DEVELOPED. BR-FF ARE BEING USED WITH HGMS SUCCESSFULLY FOR DOING IMMUNOASSAYS AND TOGETHER THEY REPRESENT A SIGNIFICANT STEP FORWARD IN THE FIELD OFFERING NUMEROUS ADVANTAGES OVER PRIOR SYSTEMS. THE SPECIFIC AIMS ARE TO DETERMINE IF BR-FF AS CURRENTLY SYNTHESIZED OR AS SYNTHESIZED BY RELATIVELY STRAIGHTFORWARD MODIFICATION CAN WITHSTAND THE RIGORS OF DESORPTION (LOW PH, DENATURANTS, KAOTROPIC IONORS (HGMS) AND IMPROVED SYSTEMS CURRENTLY BEING DEVELOPED. BR-FF ARE BEING USED WITH HGMS SUCCESSFULLY FOR DOING IMMUNOASSAYS AND TOGETHER THEY REPRESENT A SIGNIFICANT STEP FORWARD IN THE FIELD OFFERING NUMEROUS ADVANTAGES OVER PRIOR SYSTEMS. THE SPECIFIC AIMS ARE TO DETERMINE IF BR-FF AS CURRENTLY SYNTHESIZED OR AS SYNTHESIZED BY RELATIVELY STRAIGHTFORWARD MODIFICATION CAN WITHSTAND THE RIGORS OF DESORPTION (LOW PH, DENATURANTS, KAOTROPIC IONS) AND RECYCLING. AFFINITY SEPARATIONS CURRENTLY PLAY A MINOR ROLE IN BIOPROCESSING IN PART BECAUSE OF COST AND THE NATURE OF AFFINITY SUPPORTS (PARTICLES OR MEMBRANES) WHICH ARE CONSTRAINED TO BATCH MODE AND ULTRA CLEAN SOLUTIONS. BR-FF AND HGMS OFFERS THE POTENTIAL FOR CONTINUOUS AFFINITY SEPARATION WHICH CAN FUNCTION IN THE PRESENCE OF MAJOR SOLUTION CONTAMINANTS INCLUDING SOLIDS; THUS A NEW BIOPROCESSING TECHNOLOGY WHICH ALSO REQUIRES SIGNIFICANTLY LESS PROCESSING STEPS IS POSSIBLE.

Principal Investigator:

Liberti, Paul A
Principal Investigator
2159380100

Business Contact:

1 r43 hl46073-01
Small Business Information at Submission:

Immunicon Corpon
1310 Masons Mill Ii Huntingdon Valley, PA 19006

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No